A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effective

References

• Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5(5):1–10. doi: 10.1016/j.ijwd.2019.06.026.
   PubMedGoogle Scholar
• Zouboulis CC, Bechara FG, Fritz K, et al. S1 guideline for the treatment of hidradenitis suppurativa/acne inversa * (number ICD-10 L73.2). JDDG. 2012;10(Suppl 5):s 1–31.
   Google Scholar
• Jemec GB. Hidradenitis suppurativa. J Cutan Med Surg. 2003;7(1):47–56. doi: 10.1177/120347540300700109.
   PubMed Web of Science ®Google Scholar
• Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69(5):819. doi: 10.1016/j.jaad.2013.06.042.
   PubMed Web of Science ®Google Scholar
• Garg A, Papagermanos V, Midura M, et al. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol. 2018;178(3):709–714. doi: 10.1111/bjd.15939.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546–1549. doi: 10.1111/bjd.14038.
   PubMed Web of Science ®Google Scholar
• Yao Y, Jørgensen AR, Thomsen SF. Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study. Int J Dermatol. 2020;59(3):333–340. doi: 10.1111/ijd.14706.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152(4):429–434. doi: 10.1001/jamadermatol.2015.6264.
   PubMed Web of Science ®Google Scholar
• Kirsten N, Frings V, Nikolakis GD, et al. Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa. Hautarzt. 2021;72(8):651–657. doi: 10.1007/s00105-021-04851-z.
   PubMed Web of Science ®Google Scholar
• Garg A, Neuren E, Cha D, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. 2020;82(2):366–376. doi: 10.1016/j.jaad.2019.06.1301.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–644. doi: 10.1111/jdv.12966.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the european guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343–351. doi: 10.1007/s11154-016-9328-5.
   PubMed Web of Science ®Google Scholar
• Frings VG, Schöffski O, Goebeler M, et al. Correction: economic analysis of the costs associated with hidradenitis suppurativa at a german university hospital. PLoS One. 2021;16(9):e0257481. doi: 10.1371/journal.pone.0257481.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Landells IDR, Morgan D, et al. Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease. J Cutan Med Surg. 2018;22(1):71–77. doi: 10.1177/1203475417736290.
   PubMed Web of Science ®Google Scholar
• Schultheis M, Grabbe S, Staubach P, et al. Clinical features of persons suffering from acne inversa. Dtsch Arztebl Int. 2023;120(19):345–346.
   PubMed Web of Science ®Google Scholar
• Schultheis M, Staubach P, Nikolakis G, et al. A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial. Br J Dermatol. 2023;189(2):170–179. doi: 10.1093/bjd/ljad135.
   PubMed Web of Science ®Google Scholar
• Basra MKA, Fenech R, Gatt RM, et al. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035. doi: 10.1111/j.1365-2133.2008.08832.x.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Tzellos T, Kyrgidis A, European Hidradenitis Suppurativa Foundation Investigator Group., et al. Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–1409. doi: 10.1111/bjd.15748.
   PubMed Web of Science ®Google Scholar
• National Institute for H, Care E. NICE Process and Methods Guides. Guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence (NICE). Copyright © 2013 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved; 2013.
   Google Scholar
• Ali FM, Kay R, Finlay AY, et al. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res. 2017;26(11):3025–3034. doi: 10.1007/s11136-017-1607-4.
   PubMed Web of Science ®Google Scholar
• Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4(3):222–231. doi: 10.1007/s10198-003-0182-5.
   PubMedGoogle Scholar
• Kirby JS, Miller JJ, Adams DR, et al. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150(9):937–944. doi: 10.1001/jamadermatol.2014.691.
   PubMed Web of Science ®Google Scholar
• Bodenheimer T, Fernandez A. High and rising health care costs. Part 4: can costs be controlled while preserving quality? Ann Intern Med. 2005;143(1):26–31. doi: 10.7326/0003-4819-143-1-200507050-00007.
   PubMed Web of Science ®Google Scholar
• Gáspár K, Hunor Gergely L, Jenei B, et al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):399–408. doi: 10.1080/14737167.2021.1895753.
   PubMed Web of Science ®Google Scholar
• Kosunen MP, Ranta M, Hirvonen M, et al. Pss22 – economic burden of disease of hidradenitis suppurativa IN Finland: results FROM THE hi-fi study. Value in Health. 2018;21:S426. doi: 10.1016/j.jval.2018.09.2522.
   Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761. doi: 10.1016/S0140-6736(23)00022-3.
   PubMed Web of Science ®Google Scholar
• Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279–1288. doi: 10.1001/jamadermatol.2021.2905.
   PubMed Web of Science ®Google Scholar
• Kirsten N, Petersen J, Hagenström K, et al. Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34(1):174–179. doi: 10.1111/jdv.15940.
   PubMed Web of Science ®Google Scholar
• Marvel J, Vlahiotis A, Sainski-Nguyen A, et al. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open. 2019;9(9):e030579. doi: 10.1136/bmjopen-2019-030579.
   PubMed Web of Science ®Google Scholar
• Calao M, Wilson JL, Spelman L, et al. Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PLoS One. 2018;13(7):e0200683. doi: 10.1371/journal.pone.0200683.
   PubMed Web of Science ®Google Scholar
• Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, et al. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577–590. doi: 10.1016/j.ad.2016.04.018.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Yuasa A, Yonemoto N, et al. A systematic literature review of economic evaluations and cost studies of the treatment of psoriasis, atopic dermatitis, and chronic urticaria. Dermatol Ther (Heidelb). 2022;12(8):1729–1751. doi: 10.1007/s13555-022-00774-2.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Yang H, Mu F, et al. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181(1):147–154. doi: 10.1111/bjd.17101.
   PubMed Web of Science ®Google Scholar